Teva Launches Website to Support Schizophrenia Care with Long-Acting Injectables
News related to:Teva Pharmaceuticals · 1 min read
Teva Pharmaceuticals has launched a new educational website, LongActingImpact.com, aimed at supporting healthcare providers in having informed treatment discussions with patients living with schizophrenia. The website focuses on long-acting injectables (LAIs), which offer an opportunity to improve adherence and potential outcomes for patients with schizophrenia.
According to Teva, LAIs can reduce the risk of relapse and protect patient outcomes. The website provides healthcare providers with information on strategies to ensure consistent treatment delivery when patients struggle with adherence to daily medication. It also addresses how LAIs can support continuity of care, particularly during the critical transition from inpatient to outpatient settings.
Teva's commitment to supporting clinicians is evident in the development of this resource center. Verena Ramirez Campos, Vice President of U.S. Medical Affairs and Global Innovative Strategy at Teva, emphasized the importance of considering LAIs as a treatment option.
The website offers step-by-step guidance for navigating patient conversations, from identifying life goals to building trust through open, ongoing dialogue. It highlights that 67% of patients taking oral medications for schizophrenia were nonadherent or stopped taking them altogether. Long-acting treatment options, like LAIs, may help people who struggle with taking a daily medication.
Despite the potential benefits, LAIs remain underutilized due to perceived patient resistance and operational complexities.
Teva's initiative is part of its broader commitment to advancing schizophrenia care. The company, a leader in neuroscience, believes that by providing evidence-based resources, it can help improve the lives of people living with schizophrenia. The website is available online for any healthcare providers seeking information.
The launch of LongActingImpact.com underscores Teva's dedication to addressing the challenges of schizophrenia care, particularly medication adherence. By empowering clinicians with the right resources, the company aims to support more informed and effective treatment decisions.